Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG Gets European Approval of VEGF Trap-Eye to Treat AMD-DJ


Tuesday, 27 Nov 2012 02:16am EST 

Dow Jones reported that Bayer AG has received European Commission approval for EYLEA, also known as VEGF Trap-Eye, to treat wet age-related macular degeneration. The treatment is already approved in the United States, Australia and Japan. The Company also said that it will launch EYLEA in Japan soon. 

Company Quote

137.7
-0.09 -0.07%
3:13pm EDT